| Mutations and prognosis in primary myelofibrosis AM Vannucchi, TL Lasho, P Guglielmelli, F Biamonte, A Pardanani, ... Leukemia 27 (9), 1861-1869, 2013 | 873 | 2013 |
| The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients P Guglielmelli, TL Lasho, G Rotunno, J Score, C Mannarelli, A Pancrazzi, ... Leukemia 28 (9), 1804-1810, 2014 | 345 | 2014 |
| Ferroptosis and cancer: mitochondria meet the “iron maiden” cell death AM Battaglia, R Chirillo, I Aversa, A Sacco, F Costanzo, F Biamonte Cells 9 (6), 1505, 2020 | 335 | 2020 |
| EZH2 mutational status predicts poor survival in myelofibrosis P Guglielmelli, F Biamonte, J Score, C Hidalgo-Curtis, F Cervantes, ... Blood, The Journal of the American Society of Hematology 118 (19), 5227-5234, 2011 | 306 | 2011 |
| Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis P Guglielmelli, G Barosi, A Rambaldi, R Marchioli, A Masciulli, L Tozzi, ... Blood, The Journal of the American Society of Hematology 118 (8), 2069-2076, 2011 | 181 | 2011 |
| Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study P Guglielmelli, F Biamonte, G Rotunno, V Artusi, L Artuso, I Bernardis, ... Blood, The Journal of the American Society of Hematology 123 (14), 2157-2160, 2014 | 156 | 2014 |
| MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer F Biamonte, G Santamaria, A Sacco, FM Perrone, A Di Cello, AM Battaglia, ... Scientific reports 9 (1), 5668, 2019 | 95 | 2019 |
| Targeting cardiac stem cell senescence to treat cardiac aging and disease E Cianflone, M Torella, F Biamonte, A De Angelis, K Urbanek, ... Cells 9 (6), 1558, 2020 | 94 | 2020 |
| Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms E Tenedini, I Bernardis, V Artusi, L Artuso, E Roncaglia, P Guglielmelli, ... Leukemia 28 (5), 1052-1059, 2014 | 83 | 2014 |
| Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition N Lobello, F Biamonte, ME Pisanu, MC Faniello, Ž Jakopin, E Chiarella, ... Oncotarget 7 (38), 62019, 2016 | 76 | 2016 |
| Iron metabolism in the tumor microenvironment—Implications for anti-cancer immune response A Sacco, AM Battaglia, C Botta, I Aversa, S Mancuso, F Costanzo, ... Cells 10 (2), 303, 2021 | 69 | 2021 |
| Ferritin heavy subunit enhances apoptosis of non-small cell lung cancer cells through modulation of miR-125b/p53 axis F Biamonte, AM Battaglia, F Zolea, DM Oliveira, I Aversa, G Santamaria, ... Cell Death & Disease 9 (12), 1174, 2018 | 59 | 2018 |
| Epithelial-to-mesenchymal transition in FHC-silenced cells: the role of CXCR4/CXCL12 axis I Aversa, F Zolea, C Ieranò, S Bulotta, AM Trotta, MC Faniello, C De Marco, ... Journal of Experimental & Clinical Cancer Research 36, 1-15, 2017 | 56 | 2017 |
| H‐Ferritin Affects Cisplatin‐Induced Cytotoxicity in Ovarian Cancer Cells through the Modulation of ROS A Salatino, I Aversa, AM Battaglia, A Sacco, A Di Vito, G Santamaria, ... Oxidative medicine and cellular longevity 2019 (1), 3461251, 2019 | 49 | 2019 |
| Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F-mutated SET2 cells S Bortoluzzi, A Bisognin, M Biasiolo, P Guglielmelli, F Biamonte, R Norfo, ... Blood, The Journal of the American Society of Hematology 119 (13), e120-e130, 2012 | 47 | 2012 |
| Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility F Biamonte, C Botta, M Mazzitelli, S Rotundo, EM Trecarichi, D Foti, ... Journal of translational medicine 19, 1-10, 2021 | 39 | 2021 |
| Iron administration overcomes resistance to erastin-mediated ferroptosis in ovarian cancer cells AM Battaglia, A Sacco, ID Perrotta, MC Faniello, M Scalise, D Torella, ... Frontiers in oncology 12, 868351, 2022 | 37 | 2022 |
| H-ferritin-regulated microRNAs modulate gene expression in K562 cells F Biamonte, F Zolea, A Bisognin, M Di Sanzo, C Saccoman, D Scumaci, ... PLoS One 10 (3), e0122105, 2015 | 37 | 2015 |
| FTH1 pseudogenes in cancer and cell metabolism M Di Sanzo, B Quaresima, F Biamonte, C Palmieri, MC Faniello Cells 9 (12), 2554, 2020 | 34 | 2020 |
| shRNA targeting of ferritin heavy chain activates H19/miR-675 axis in K562 cells M Di Sanzo, R Chirillo, I Aversa, F Biamonte, G Santamaria, ... Gene 657, 92-99, 2018 | 33 | 2018 |
